Bimatoprost

Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus[1][2][3][4][5][6].

Product Specifications

CAS Number

[155206-00-1]

Product Name Alternative

AGN 192024

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MMP; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Field of Research

Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Bimatoprost.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C[C@@H]1O

Molecular Formula

C25H37NO4

Molecular Weight

415.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Park J, et al. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011 Jan;55 (1) :22-7.|[2]Filippopoulos T, et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008 Jul-Aug;24 (4) :302-7.|[3]Stamer W D, et al. Proposed mechanism of long-term intraocular pressure lowering with the bimatoprost implant[J]. Investigative Ophthalmology & Visual Science, 2023, 64 (3) : 15-15.|[4]Patil A J, et al. Bimatoprost–a review[J]. Expert opinion on pharmacotherapy, 2009, 10 (16) : 2759-2768.|[5]Woodward, et al. "Bimatoprost: a novel antiglaucoma agent." Cardiovascular drug reviews 22.2 (2004) : 103-120.|[6]Crowston, et al. "Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice." Investigative ophthalmology & visual science 46.12 (2005) : 4571-4577.